




**MOL2NET'22, Conference on
Molecular, Biomedical &
Computational Sciences and
Engineering, 8th ed.**



Engineering protein fragments via evolutionary and protein-protein interaction algorithms: *De novo* design of peptide inhibitors for FoF₁-ATP synthase


Yasser B. Ruiz-Blanco^{a,b†}, Luis Pablo Ávila-Barrientos^{a†}, Enrique Hernández-García^a, Agostinho Antunes^{c,d}, Guillermin Agüero-Chapin^{c,d} and Enrique García-Hernández^{a*}*

^a Universidad Nacional Autónoma de México, Instituto de Química, Ciudad de México, 04510, México.

^b Computational Biochemistry, Center of Medical Biotechnology, University of Duisburg-Essen, Essen, 45127, Germany.

^c CIIMAR - Centro Interdisciplinar de Investigação Marinha e Ambiental, 4450-208 Porto, Portugal.

^d Departamento de Biologia, Universidade do Porto, 4169-007 Porto, Portugal.



Abstract: Enzyme's subunits interfaces have remarkable potential in drug design as both target and scaffold for their own inhibitors. We show an evolution-driven strategy for the *de novo* design of peptide inhibitors targeting interfaces of the *E. coli*'s FoF1-ATP synthase as a case study. The evolutionary algorithm ROSE is applied to generate diversity-oriented peptide libraries by engineering peptide fragments from ATP synthase interfaces. The resulting peptides are scored with PPI-Detect, a sequence-based predictor of protein-protein interactions. Two selected peptides were confirmed by *in vitro* inhibition and binding tests. The proposed methodology can be widely applied to design peptides targeting relevant interfaces of enzymatic complexes (<https://doi.org/10.1002/1873-3468.13988>).

The main bibliographic sources used in this paper are listed below [1-10].

References

1. Henninot, A., J.C. Collins, and J.M. Nuss, *The Current State of Peptide Drug Discovery: Back to the Future?* J Med Chem, 2018. **61**(4): p. 1382-1414.
2. Bozovicar, K. and T. Bratkovic, *Evolving a Peptide: Library Platforms and Diversification Strategies*. Int J Mol Sci, 2019. **21**(1).
3. Muller, A.T., et al., *modLAMP: Python for antimicrobial peptides*. Bioinformatics, 2017. **33**(17): p. 2753-2755.
4. Gabernet, G., et al., *In silico design and optimization of selective membranolytic anticancer peptides*. Sci Rep, 2019. **9**(1): p. 11282.
5. Stoye, J., D. Evers, and F. Meyer, *Rose: generating sequence families*. Bioinformatics, 1998. **14**(2): p. 157-63.
6. Romero-Molina, S., et al., *PPI-Detect: A support vector machine model for sequence-based prediction of protein-protein interactions*. J Comput Chem, 2019. **40**(11): p. 1233-1242.
7. Romero-Molina, S., et al., *ProtDCal-Suite: A web server for the numerical codification and functional analysis of proteins*. Protein Sci, 2019. **28**(9): p. 1734-1743.

-
8. Ahmad, Z., et al., *ATP synthase: a molecular therapeutic drug target for antimicrobial and antitumor peptides.* Curr Med Chem, 2013. **20**(15): p. 1956-73.
 9. erdih, A., et al., *Inhibitor design strategy based on an enzyme structural flexibility: a case of bacterial MurD ligase.* J Chem Inf Model, 2014. **54**(5): p. 1451-66.
 10. Mosca, R., et al., *3did: a catalog of domain-based interactions of known three-dimensional structure.* Nucleic Acids Res, 2014. **42**(Database issue): p. D374-9.